Alexion, the US-listed biopharmaceutical company, is said to have drawn interest from rival acquirers after it emerged Biogen is circling the business.
This is paywall protected Betaville Intelligence content. You need to purchase a subscription to access this content. Or get in touch with subscription sales at [email protected] to find out about the different subscription packages on offer.
